You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 22, 2025

Details for Patent: 11,179,434


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 11,179,434 protect, and when does it expire?

Patent 11,179,434 protects QBRELIS and is included in one NDA.

This patent has ten patent family members in eight countries.

Summary for Patent: 11,179,434
Title:Lisinopril formulations
Abstract:Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.
Inventor(s):Gerold L. Mosher, David W. Miles
Assignee:Azurity Pharmaceuticals Inc
Application Number:US17/194,021
Patent Claim Types:
see list of patent claims
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 11,179,434: A Comprehensive Analysis

Introduction

When analyzing a patent, particularly one like United States Patent 11,179,434, it is crucial to delve into the specifics of its scope, claims, and the broader patent landscape. This article will provide a detailed examination of these aspects, helping business professionals and inventors navigate the complexities of patent law and strategy.

Patent Scope and Claims

Definition and Importance

Patent scope refers to the breadth and depth of protection granted by a patent, which is primarily defined by the patent claims. The claims are the legal boundaries of what the patent protects, and they must be clear, concise, and supported by the patent's description[3].

Metrics for Measuring Patent Scope

Researchers often use metrics such as independent claim length and independent claim count to measure patent scope. These metrics can indicate the breadth and complexity of the patent. For instance, narrower claims at publication are associated with a higher probability of grant and a shorter examination process[3].

The Specifics of United States Patent 11,179,434

Patent Claims

To analyze the scope of Patent 11,179,434, one must carefully review its claims. Here are some key points to consider:

  • Independent Claims: These are the broadest claims in the patent and define the core invention. They are crucial for understanding the patent's scope.
  • Dependent Claims: These claims are narrower and build upon the independent claims, providing additional details and limitations.
  • Claim Language: The clarity and specificity of the claim language are vital. Broader claims can be risky as they may be more susceptible to invalidation due to prior art or obviousness[3].

Claim Construction

Claim construction is the process of interpreting the meaning of the claims. This is often a critical issue in patent litigation and can significantly impact the patent's scope. The courts use various rules and guidelines to construct claims, ensuring they are consistent with the patent's specification and prosecution history.

Patent Landscape and Context

Patent Term and Expiration

The patent term in the United States is generally 20 years from the effective filing date, as amended by the Uruguay Round Agreements Act (URAA)[2]. Understanding the patent term is essential for determining the patent's expiration date and any potential extensions or adjustments.

Obviousness-Type Double Patenting (ODP)

ODP is a doctrine that prevents an inventor from securing a second, later-expiring patent for an invention covered by a patent that was filed at the same time but has a different patent term due to a grant of Patent Term Adjustment (PTA) or Patent Term Extension (PTE). This doctrine is crucial in ensuring that patents do not extend beyond their intended term and to prevent abuse of the patent system[1].

Restriction Requirements

The Patent and Trademark Office (PTO) may issue restriction requirements if an application discloses multiple independent and distinct inventions. This can affect the scope of the patent by requiring the applicant to choose which claims to pursue in a single application[2].

Legal and Regulatory Framework

URAA and Patent Term Changes

The URAA changed the patent term from 17 years from the grant date to 20 years from the effective filing date. This change aimed to promote timely disclosure of innovations and reduce the incentives for delaying patent prosecution[2].

Ex Parte Reexamination

Ex parte reexamination is a process where the PTO reexamines an existing patent based on new prior art or other grounds. This process can impact the patent's scope if claims are found to be unpatentable over prior art or due to ODP[1].

Practical Considerations for Inventors and Business Professionals

Patent Strategy

When developing a patent strategy, it is essential to consider the scope and claims of the patent. Narrower claims may be more likely to be granted quickly, but they offer less protection. Broader claims, while offering more protection, are riskier and may face more challenges during prosecution and litigation[3].

Licensing and Litigation

The scope and claims of a patent significantly impact licensing and litigation strategies. Clear and well-defined claims can reduce licensing and litigation costs by providing a clear understanding of what is protected[3].

Case Studies and Precedents

In re Cellect

The case of In re Cellect highlights the importance of ODP in preventing the extension of patent terms beyond their intended duration. It also underscores the need for careful analysis of patent claims and their relationship to other patents within the same family[1].

Hyatt v. PTO

Hyatt v. PTO illustrates the complexities of restriction requirements and the impact of URAA on patent prosecution. This case shows how changes in patent law and regulations can affect the scope and claims of patents[2].

Key Takeaways

  • Clear Claims: Ensure that patent claims are clear, concise, and supported by the patent's description.
  • Patent Scope Metrics: Use metrics like independent claim length and count to measure and optimize patent scope.
  • ODP Considerations: Be aware of ODP to avoid extending patent terms beyond their intended duration.
  • Regulatory Changes: Understand the impact of regulatory changes like URAA on patent terms and prosecution.
  • Strategic Planning: Develop a patent strategy that balances the breadth of claims with the risks and benefits.

FAQs

Q: What is the significance of independent claim length and count in measuring patent scope? A: Independent claim length and count are metrics that help measure the breadth and complexity of a patent. Narrower claims are associated with a higher probability of grant and a shorter examination process[3].

Q: How does the URAA affect patent terms in the United States? A: The URAA changed the patent term from 17 years from the grant date to 20 years from the effective filing date, promoting timely disclosure of innovations[2].

Q: What is Obviousness-Type Double Patenting (ODP), and why is it important? A: ODP prevents an inventor from securing a second, later-expiring patent for an invention covered by a patent that was filed at the same time but has a different patent term due to a grant of PTA or PTE[1].

Q: How do restriction requirements impact the scope of a patent? A: Restriction requirements can limit the scope of a patent by forcing the applicant to choose which claims to pursue in a single application, ensuring that only one independent and distinct invention is claimed per application[2].

Q: What are the practical implications of broader versus narrower patent claims? A: Broader claims offer more protection but are riskier and may face more challenges during prosecution and litigation. Narrower claims are more likely to be granted quickly but offer less protection[3].

Sources

  1. In re Cellect, United States Court of Appeals for the Federal Circuit, August 28, 2023.
  2. Hyatt v. PTO, United States Court of Appeals for the Federal Circuit, September 8, 2022.
  3. Patent Claims and Patent Scope, SSRN, September 29, 2016.

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 11,179,434

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Azurity QBRELIS lisinopril SOLUTION;ORAL 208401-001 Jul 29, 2016 RX Yes Yes 11,179,434 ⤷  Try for Free Y ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.